• 1
    Chakravarty B. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993; 88: 8525.
  • 2
    Travis S, Farrant J, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 90510.
  • 3
    Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporine as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10(5): 4113.
  • 4
    Van Gossum A, Schmit A, Adler M, et al. Short and long term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Acta Gastroenterol Belg 1997; 60: 197200.
  • 5
    Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41: 24716.
  • 6
    D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120(6): 13239.
  • 7
    Truelove S, Willoughby C, Lee E, Kettlewell M. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 10868.
  • 8
    Hearing S, Norman M, Smyth C, Foy C, Dayan C. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999; 84: 414954.
  • 9
    Hearing S, Norman M, Probert C, Haslam N, Dayan C. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999; 45: 3828.
  • 10
    Alvarez J, Surs W, Leung L, Ikle D, Gefland E, Szefler S. Steroid resistant asthma: immunological and pharmacological features. J Allergy Clin Immunol 1992; 89: 71421.
  • 11
    Seki M, Ushiyama C, Seta N, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheumatol 1998; 41: 82330.
  • 12
    Langhoff E, Ladefoged J, Jakobsen B, et al. Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival. Lancet 1986; 1: 12967.
  • 13
    Walker K, Potter J, House A. Interleukin-2 synthesis in the presence of steroids: a model of steroid resistance. Clin Exp Immunol 1987; 68: 1627.
  • 14
    Kam J, Szefler S, Surs W, Sher E, Leung L. Combination of IL-2 and IL-4 reduces glucocorticoid receptor binding affinity and T-cell response to glucocorticoids. J Immunol 1993; 151: 34606.
  • 15
    Irusen E, Mathews J, Takahashi A, Barnes P, Chung K, Adcock I. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109: 64957.
  • 16
    Nashan B, Moore R, Amlot P, Schmidt A, Abeywikrama K, Soulillou J. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 11938.
  • 17
    Mulloy L, Wright F, Hall M, Moore M. Basiliximab reduces acute cellular rejection in renal allografts from cadaveric and living donors. Transplant Proc 1999; 31: 12103.
  • 18
    Kovarik JM, Rawlings E, Sweny P, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28(2): 9134.
  • 19
    Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacokinetics and exposure–response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation 1999; 68(a): 12289.
  • 20
    Schroeder K, Tremaine W, Ilstrup D. Coated oral 5-aminosalicylic acid therapy for mild to moderately active ulcerative colitis. N Engl J Med 1987; 317: 16258.
  • 21
    Baron J, Connell A, Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 8992.
  • 22
    Truelove S, Witts L. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 10418.
  • 23
    Matl I, Bachleda P, Lao M, et al. Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine. Transpl Int 2003; 16(1): 4552.
  • 24
    Irvine E. A quality of life index for inflammatory bowel disease. Can J Gastroenterol 1993; 7: 1559.
  • 25
    Riley S, Mani V, Goodman M, Dutt S, Herd M. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 1748.
  • 26
    Onrust S, Wiseman L. Basiliximab. Drugs 1999; 57: 20713.
  • 27
    Cheung W, Garratt AM, Russel IT, Williams JG. The UK IBDQ — A British version of the inflammatory bowel disease questionnaire: development and validation. J Clin Epidemiol 2000; 53: 297306.
  • 28
    Probert C, Hearing S, Schreiber S. et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 997–1001.
  • 29
    Bell HK, Parslew RA. Use of basiliximab as a cyclosporin-sparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect. Br J Dermatol 2002; 147(3): 6067.
  • 30
    Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol 2000; 143(5): 11212.
  • 31
    Kagi MK, Heyer G. Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis. Br J Dermatol 2001; 145(2): 3501.
  • 32
    Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 2000; 25(3): 1957.
  • 33
    Berman JA, Patel K, Caro J. Enhanced response to basiliximab in a patient with aplastic anemia after treatment with standard immunosuppression. Am J Hematol 2002; 71(1): 64.
  • 34
    Barros VR, Rocha V, Garcia VD, Garcia CD. Anaphylactic shock after retreatment with basiliximab. Transpl Proc 2003; 35(1): 579.
  • 35
    Blam M, Stein R, Lichtenstein G. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2002; 96: 197797.
  • 36
    Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanised anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98: 36976.
  • 37
    Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000; 118: 85966.
  • 38
    Bantel H, Domschke W, Schulze-Osthoff K. Molecular mechanisms of glucocorticoid resistance. Gastroenterology 2000; 119: 11789.
  • 39
    Ellery J, Nicholls P. Alternate signalling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev 2002; 13: 2730.
  • 40
    Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between stat5 and the glucocorticoid receptor. Nature 1996; 383: 7268.
  • 41
    Biola A, Lefebvre P, Perrin-Wolff M, Sturm M, Bertoglio J, Pallardy M. Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving Stat5 (signal transducer and activator of transcription 5) but not AP-1. Mol Endocrinol 2001; 15: 106276.
  • 42
    Jamieson C, Yamamoto K. Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T-cell receptor signalling. Proc Natl Acad Sci USA 2000; 97: 731924.
  • 43
    Rogatsky I, Logan S, Garabedian M. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA 1998; 95: 20505.